| Literature DB >> 31940267 |
Anna B Morris1, Clara R Farley1, David F Pinelli1, Layne E Adams1, Mark S Cragg2, Jeremy M Boss3, Christopher D Scharer3, Miguel Fribourg4, Paolo Cravedi4, Peter S Heeger4, Mandy L Ford5.
Abstract
Effector CD8+ T cells are important mediators of adaptive immunity, and receptor-ligand interactions that regulate their survival may have therapeutic potential. Here, we identified a subset of effector CD8+ T cells that expressed the inhibitory fragment crystallizable (Fc) receptor FcγRIIB following activation and multiple rounds of division. CD8+ T cell-intrinsic genetic deletion of Fcgr2b increased CD8+ effector T cell accumulation, resulting in accelerated graft rejection and decreased tumor volume in mouse models. Immunoglobulin G (IgG) antibody was not required for FcγRIIB-mediated control of CD8+ T cell immunity, and instead, the immunosuppressive cytokine fibrinogen-like 2 (Fgl2) was a functional ligand for FcγRIIB on CD8+ T cells. Fgl2 induced caspase-3/7-mediated apoptosis in Fcgr2b+, but not Fcgr2b-/-, CD8+ T cells. Increased expression of FcγRIIB correlated with freedom from rejection following withdrawal from immunosuppression in a clinical trial of kidney transplant recipients. Together, these findings demonstrate a cell-intrinsic coinhibitory function of FcγRIIB in regulating CD8+ T cell immunity.Entities:
Keywords: CD8(+) T cells; FcgRIIB; Fgl2; apoptosis; transplantation; tumor immunology
Mesh:
Substances:
Year: 2020 PMID: 31940267 PMCID: PMC7326381 DOI: 10.1016/j.immuni.2019.12.006
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745